• Viking Therapeutics (VKTX) shares are up 3.6% at $40.11, following a reiterated 'Overweight' rating and $71.00 price target from Piper Sandler.
  • The stock is also gaining renewed attention after the company launched a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss.
  • This progress comes as the company continues to advance its late-stage obesity candidate VK2735 and amid a generally mixed broader market environment.